Codagenix
Farmingdale
About Codagenix
Codagenix is a developer of live-attenuated viral vaccines to provide target antigens placed in an attenuated backbone virus. Its vaccines utilize Synthetic Attenuated Virus Engineering (SAVE), which are based on synthetic biology and are rationally re-designed of the entire genome to yield a vaccine strain.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $65.6M
- Funding stage: Early Stage Venture
- Last round: Grant (Oct 2023)
- Website: codagenix.com
- Phone: 5168290353
Industries & Categories
Biotechnology, Genetics, Medical
Social Profiles
Canonical: https://fsome.com/organization/codagenix-60057 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.